RALGDS FAMILY MEMBERS INTERACT WITH THE EFFECTOR LOOP OF RAS P21

被引:256
|
作者
KIKUCHI, A [1 ]
DEMO, SD [1 ]
YE, ZH [1 ]
CHEN, YW [1 ]
WILLIAMS, LT [1 ]
机构
[1] UNIV CALIF SAN FRANCISCO,CARDIOVASC RES INST,SAN FRANCISCO,CA 94143
关键词
D O I
10.1128/MCB.14.11.7483
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Using a yeast two-hybrid system, we identified a novel protein which interacts with ras p21. This protein shares 69% amino acid homology with ral guanine nucleotide dissociation stimulator (ralGDS), a GDP/GTP exchange protein for ral p24. We designated this protein RGL, for ralGDS-like. Using the yeast two-hybrid system, we found that an effector loop mutant of ras p21 was defective in interacting with the ras p21-interacting domain of RGL; suggesting that this domain binds to ras p21 through the effector loop of ras p21. Since ralGDS contained a region highly homologous with the ras p21-interacting domain of RGL, we examined whether ralGDS could interact with ras p21. In the yeast two-hybrid system, ralGDS failed to interact with an effector loop mutant of ras p21. In insect cells, ralGDS made a complex with v-ras p21 but not with a dominant negative mutant of ras p21. ralGDS interacted with the GTP-bound form of ras p21 but not with the GDP-bound form in vitro. ralGDS inhibited both the GTPase-activating activity of the neurofibromatosis gene product (NF1) for pas p21 and the interaction of Raf with vas p21 in vitro. These results demonstrate that ralGDS specifically interacts with the active form of ras p21 and that ralGDS can compete with NF1 and Raf fbr binding to the effector loop of ras p21. Therefore, ralGDS family members may be effector proteins of ras p21 or play inhibit interactions between ras p21 and its effecters.
引用
收藏
页码:7483 / 7491
页数:9
相关论文
共 50 条
  • [32] ras基因产物P21与妇科肿瘤
    丁丽珠
    江西医学院学报, 1995, (02) : 77 - 79
  • [33] BIOCHEMICAL-PROPERTIES OF NORMAL AND ONCOGENIC RAS P21
    GIBBS, JB
    SIGAL, IS
    SCOLNICK, EM
    TRENDS IN BIOCHEMICAL SCIENCES, 1985, 10 (09) : 350 - 353
  • [34] EXPRESSION OF RAS P21 IN BENIGN AND MALIGNANT THYROID LESIONS
    TSELENIBALAFOUTA, S
    GONOS, ES
    SPANDIDOS, DA
    ONCOLOGY REPORTS, 1994, 1 (01) : 107 - 110
  • [35] INTERACTION OF RAS P21 PROTEINS WITH GTPASE ACTIVATING PROTEIN
    MCCORMICK, F
    ADARI, H
    TRAHEY, M
    HALENBECK, R
    KOTHS, K
    MARTIN, GA
    CROSIER, WJ
    WATT, K
    RUBINFELD, B
    WONG, G
    COLD SPRING HARBOR SYMPOSIA ON QUANTITATIVE BIOLOGY, 1988, 53 : 849 - 854
  • [36] IMMUNOCYTOCHEMICAL DEMONSTRATION AND SIGNIFICANCE OF P21 RAS FAMILY ONCOGENE PRODUCT IN BENIGN AND MALIGNANT BREAST DISEASE
    CANDLISH, W
    KERR, IB
    SIMPSON, HW
    JOURNAL OF PATHOLOGY, 1986, 150 (03): : 163 - 167
  • [37] A MODEL FOR THE TERTIARY STRUCTURE OF P21, THE PRODUCT OF THE RAS ONCOGENE
    MCCORMICK, F
    CLARK, BFC
    LACOUR, TFM
    KJELDGAARD, M
    NORSKOVLAURITSEN, L
    NYBORG, J
    JOURNAL OF CELLULAR BIOCHEMISTRY, 1986, : 23 - 23
  • [38] THE REGULATION OF ENDOTHELIAL-CELL MOTILITY BY P21 RAS
    FOX, PL
    SA, G
    DOBROWOLSKI, SF
    STACEY, DW
    ONCOGENE, 1994, 9 (12) : 3519 - 3526
  • [39] Differential regulation of apoptotic pathways in lymphocytes by p21(RAS).
    Chen, CY
    Liou, J
    Forman, LW
    Faller, DV
    BLOOD, 1997, 90 (10) : 607 - 607
  • [40] NMR-STUDIES OF RAS P21 AND HIV PROTEASE
    CAMPBELLBURK, S
    DELOSKEY, R
    VANAKEN, T
    DOMAILLE, P
    WEBER, P
    HILLMAN, M
    YATES, R
    LAUE, E
    JOURNAL OF CELLULAR BIOCHEMISTRY, 1993, : 203 - 203